References
- Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2023;67:ard-2023–224762. Available from: https://ard.bmj.com/lookup/doi/10.1136/ard-2023-224762
- Ugarte A, Porta S, Ríos R, et al. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity. Lupus. 2018;27:1718–1722.
- The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324:150–154. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM199101173240303
- Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69:20–28.
- Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16:155–166.
- Sundelin SP, Terman A. Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. APMIS. 2002;110:481–489.
- Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186:4794–4804.
- An J, Minie M, Sasaki T, et al. Antimalarial drugs as immune modulators: new mechanisms for old drugs. Annu Rev Med. 2017;68(1):317–330.
- van den Borne BE, Dijkmans BA, de Rooij HH, et al. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol. 1997;24:55–60.
- McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med. 1983;75:11–18.
- Browning DJ. Pharmacology of Chloroquine and Hydroxychloroquine. Hydroxychloroquine Chloroquine Retin. New York NY: Springer New York; 2014. p. 35–63. Available from: http://link.springer.com/10.1007/978-1-4939-0597-3_2
- Rainsford KD, Parke AL, Clifford-Rashotte M, et al. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23:231–269. doi: 10.1007/s10787-015-0239-y
- Ugarte-Gil MF, Wojdyla D, Pastor-Asurza CA, et al. Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort. Lupus. 2018;27:536–544.
- Zen M, Saccon F, Gatto M, et al. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission. Rheumatology (Oxford). 2020;59(7):1591–1598. doi: 10.1093/rheumatology/kez422
- Almeida-Brasil CC, Hanly JG, Urowitz M, et al. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2022;81(3):370–378.
- Babaoglu H, Li J, Goldman D, et al. Predictors of predominant Lupus Low Disease Activity State (LLDAS-50). Lupus. 2019;28:1648–1655. Available from: http://journals.sagepub.com/doi/10.1177/0961203319886028
- Hanaoka H, Iida H, Kiyokawa T, et al. Hydroxychloroquine improves the disease activity and allows the reduction of the corticosteroid dose regardless of background treatment in Japanese patients with systemic lupus erythematosus. Intern Med. 2019;58:1257–1262.
- Garg S, Unnithan R, Hansen KE, et al. Clinical significance of monitoring hydroxychloroquine levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2021;73:707–716.
- Ruiz-Irastorza G, Ruiz-Estevez B, Lazaro E, et al. Prolonged remission in SLE is possible by using reduced doses of prednisone: an observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts. Autoimmun Rev. 2019;18:102359.
- Fessler BJ, Alarcón GS, McGwin GJ, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52:1473–1480.
- Bruce IN, O’Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2015;74:1706–1713.
- Kernder A, Richter JG, Fischer-Betz R, et al. Quality of care predicts outcome in systemic lupus erythematosus: a cross-sectional analysis of a German long-term study (LuLa cohort). Lupus. 2020;29:136–143.
- Pons-Estel GJ, Alarcón GS, McGwin GJ, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009;61:830–839.
- Reátegui-Sokolova C, Ugarte-Gil MF, Harvey GB, et al. Predictors of renal damage in systemic lupus erythematous patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL). RMD Open. 2020;6:e001299. Available from: https://rmdopen.bmj.com/lookup/doi/10.1136/rmdopen-2020-001299
- Ugarte A, Garcia de Bustos A, Ruiz-Arruza I, et al. Anti-phospholipid antibodies do not predict damage in SLE patients in the 21st century—an observational study from the Lupus-Cruces cohort. Rheumatology. 2021;61:249–257. doi: 10.1093/rheumatology/keab307
- Ruiz-Irastorza G, Egurbide M-V, Pijoan J-I, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15:577–583. Available from: http://journals.sagepub.com/doi/10.1177/0961203306071872
- Tektonidou MG, Laskari K, Panagiotakos DB, et al. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Care Res (Hoboken). 2008;61:29–36. Available from: https://onlinelibrary.wiley.com/doi/10.1002/art.24232
- González-Echavarri C, Capdevila O, Espinosa G, et al. Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort. Lupus. 2018;27:2253–2261.
- Pimentel-Quiroz VR, Ugarte-Gil MF, Harvey GB, et al. Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort. Lupus. 2019;28:1101–1110.
- Zamora LD, Collante MTM, Navarra SV. Risk factors for herpes zoster infection among Filipinos with systemic lupus erythematosus. Int J Rheum Dis. 2020;23:197–202.
- Yeo K-J, Chen -H-H, Chen Y-M, et al. Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study. BMC Infect Dis. 2020;20:112.
- Fasano S, Iudici M, Coscia MA, et al. Influence of hydroxychloroquine blood levels on adhesion molecules associated with endothelial dysfunction in patients with systemic lupus erythematosus. Lupus Sci Med. 2022;9:e000681. Available from: https://lupus.bmj.com/lookup/doi/10.1136/lupus-2022-000681
- Hage MP, Badri MR, Azar ST. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Ther Adv Endocrinol Metab. 2014;5:77–85. Available from: http://journals.sagepub.com/doi/10.1177/2042018814547204
- Bellomio V, Spindler A, Lucero E, et al. Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus. 2009;18:1019–1025. Available from: http://journals.sagepub.com/doi/10.1177/0961203309105876
- Alarcon GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66:1168–1172. Available from: https://ard.bmj.com/lookup/doi/10.1136/ard.2006.068676
- Shinjo SK, Bonfá E, Wojdyla D, et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 2010;62:855–862.
- Hsu C-Y, Lin Y-S, Cheng -T-T, et al. Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus. Rheumatology (Oxford). 2018;57:1743–1751.
- Russell MD, Dey M, Flint J, et al. Executive Summary: British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology. 2023;62:1370–1387. doi: 10.1093/rheumatology/keac558
- Huybrechts KF, Bateman BT, Zhu Y, et al. Hydroxychloroquine early in pregnancy and risk of birth defects. Am J Obstet Gynecol. 2021;224:290.e1–290.e22. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0002937820310644
- Schreiber K, Giles I, Costedoat-Chalumeau N, et al. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases. Lancet Rheumatol. 2023;5(9):e501–e506. doi: 10.1016/S2665-9913(23)00215-1
- Leroux M, Desveaux C, Parcevaux M, et al. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus. 2015;24:1384–1391.
- Seo MR, Chae J, Kim YM, et al. Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. Lupus. 2019;28(6):722–730. doi: 10.1177/0961203319843343
- Izmirly PM, Kim MY, Llanos C, et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis. 2010;69:1827–1830.
- Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent ANTI-SSA/RO-antibody–associated cardiac manifestations of neonatal lupus. Circulation. 2012;126(1):76–82.
- Barsalou J, Jaeggi E, Laskin CA, et al. Prenatal exposure to antimalarials decreases the risk of cardiac but not non-cardiac neonatal lupus: a single-centre cohort study. Rheumatology. 2017;56:1552–1559. doi: 10.1093/rheumatology/kex191
- Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132:1453–1460. Available from: http://archopht.jamanetwork.com/article.aspx?doi=10.1001/jamaophthalmol.2014.3459
- Marmor MF, Kellner U, Lai TYY, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology. 2016;123:1386–1394.
- Rosenbaum JT, Costenbader KH, Desmarais J, et al. American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 joint statement on hydroxychloroquine use with respect to retinal toxicity. Arthritis Rheumatol. 2021;73:908–911. Available from: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.41683
- de Sisternes L, Hu J, Rubin DL, et al. Localization of damage in progressive hydroxychloroquine retinopathy on and off the drug: inner versus outer retina, parafovea versus peripheral fovea. Invest Ophthalmol Vis Sci. 2015;56:3415–3426.
- Martín-Iglesias D, Artaraz J, Fonollosa A, et al. Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus. Lupus. 2019;28:555–559.
- de SCRT, Klumb EM, Minn C, et al. Evaluation of toxic retinopathy caused by antimalarial medications with spectral domain optical coherence tomography. Arq Bras Oftalmol. 2019;82:12–17.
- Mukwikwi E-R, Pineau CA, Vinet E, et al. Retinal complications in patients with systemic lupus erythematosus treated with antimalarial drugs. J Rheumatol. 2020;47:553–556.
- Wallace DJ, Gudsoorkar VS, Weisman MH, et al. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol. 2012;8:522–533.
- Sharma AN, Mesinkovska NA, Paravar T. Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review. J Am Acad Dermatol. 2020;83(2):563–578.
- Tselios K, Deeb M, Gladman DD, et al. Antimalarial-induced cardiomyopathy in systemic lupus erythematosus: as rare as considered? J Rheumatol. 2019;46:391–396.
- McGhie TK, Harvey P, Su J, et al. Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus. Clin Exp Rheumatol. 2018;36:545–551. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29652656
- Vázquez-Otero I, Medina-Cintrón N, Arroyo-Ávila M, et al. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus. Lupus Sci Med. 2020;7:e000395. Available from: https://lupus.bmj.com/lookup/doi/10.1136/lupus-2020-000395
- Jorge AM, Mancini C, Zhou B, et al. Hydroxychloroquine dose per ophthalmology guidelines and the risk of systemic lupus erythematosus flares. JAMA. 2022;328:1458. doi: 10.1001/jama.2022.13591
- Lenfant T, Costedoat-Chalumeau N. Hydroxychloroquine dose: balancing toxicity and SLE flare risk. Nat Rev Rheumatol. 2023;19:6–7. Available from: https://www.nature.com/articles/s41584-022-00868-3
- Fasano S, Messiniti V, Iudici M, et al. Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus. Lupus Sci Med. 2023;10:e000841. Available from: https://lupus.bmj.com/lookup/doi/10.1136/lupus-2022-000841
- Costedoat-Chalumeau N, Galicier L, Aumaître O, et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis. 2013;72:1786–1792. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2012-202322
- Zanetti CB, Pedrosa T, de Vk KL, et al. Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2–3 mg/kg/day): 12-month prospective randomized controlled trial. Clin Rheumatol. 2021;40(7):2745–2751.
- Andrade Balbi V, Artur Silva C, Nascimento Pedrosa T, et al. Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis. Lupus. 2022;31:97–104. Available from: http://journals.sagepub.com/doi/10.1177/09612033211062515
- Cunha C, Alexander S, Ashby D, et al. Hydroxychloroquine blood concentration in lupus nephritis: a determinant of disease outcome? Nephrol Dial Transplant. 2018;33:1604–1610. Available from: http://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfx318/4656151
- Garg S, Chewning B, Hutson P, et al. A reference range of hydroxychloroquine blood levels that can reduce odds of active lupus and prevent flares. Arthritis Care Res (Hoboken). 2023. Available from: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.25228
- Petri M, Elkhalifa M, Li J, et al. Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. Arthritis Rheumatol. 2020;72:448–453. Available from: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.41121
- Pedrosa T, de Vk KL, Pasoto SG, et al. The influence of obesity on hydroxychloroquine blood levels in lupus nephritis patients. Lupus. 2021;30:554–559.
- van Vollenhoven R, Askanase AD, Bomback AS, et al. Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. Lupus Sci Med. 2022;9:e000634. Available from: https://lupus.bmj.com/lookup/doi/10.1136/lupus-2021-000634
- Garg S, Ferguson S, Chewning B, et al. Clarifying misbeliefs about hydroxychloroquine (HCQ): developing the HCQ benefits versus harm decision aid (HCQ-SAFE) per low health literacy standards. Lupus Sci Med. 2023;10:e000935. Available from: https://lupus.bmj.com/lookup/doi/10.1136/lupus-2023-000935
- Hench PS, Kendall EC, Slocumb CH, et al. Adrenocortical hormone in arthritis : preliminary report. Ann Rheum Dis. 1949;8:97–104. Available from: https://ard.bmj.com/lookup/doi/10.1136/ard.8.2.97
- Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, et al. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology. 2014;53:1470–1476. Available from: https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/keu148
- Ruiz-Irastorza G, Ugarte A, Ruiz-Arruza I, et al. Seventy years after Hench’s Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus. Lupus. 2020;29:1155–1167. Available from: http://journals.sagepub.com/doi/10.1177/0961203320930099
- Panopoulos S, Drosos GC, Konstantonis G, et al. Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE. Lupus Sci Med. 2023;10:e000864. Available from: https://lupus.bmj.com/lookup/doi/10.1136/lupus-2022-000864
- Ugarte-Gil MF, Mak A, Leong J, et al. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Sci Med. 2021;8(1):e000590.
- Buttgereit F, Wehling M, Burmester G-R. A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. Arthritis Rheum. 1998;41:761–767. Available from: https://onlinelibrary.wiley.com/doi/10.1002/1529-0131(199805)41:5%253C761::AID-ART2%253E3.0.CO;2-M
- Buttgereit F, Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids. 2002;67:529–534. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0039128X01001714
- Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med. 2005;353:1711–1723. Available from: http://www.nejm.org/doi/10.1056/NEJMra050541
- Bekhbat M, Rowson SA, Neigh GN. Checks and balances: the glucocorticoid receptor and NFĸB in good times and bad. Front Neuroendocrinol. 2017;46:15–31. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0091302217300237
- Strehl C, Buttgereit F. Optimized glucocorticoid therapy: teaching old drugs new tricks. Mol Cell Endocrinol. 2013;380:32–40.
- Busillo JM, Cidlowski JA. The five Rs of glucocorticoid action during inflammation: ready, reinforce, repress, resolve, and restore. Trends Endocrinol Metab. 2013;24:109–119. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1043276012002159
- Buttgereit F, Straub RH, Wehling M, et al. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004;50:3408–3417. Available from: https://onlinelibrary.wiley.com/doi/10.1002/art.20583
- Lösel R, Wehling M. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol. 2003;4:46–55. Available from: https://www.nature.com/articles/nrm1009
- Stellato C. Post-transcriptional and nongenomic effects of glucocorticoids. Proc Am Thorac Soc. 2004;1:255–263. Available from: http://pats.atsjournals.org/cgi/doi/10.1513/pats.200402-015MS
- Lipworth BJ. Therapeutic implications of non-genomic glucocorticoid activity. Lancet. 2000;356:87–89. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673600024636
- Badsha H, Kong KO, Lian TY, et al. Low-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications. Lupus. 2002;11:508–513. Available from: http://journals.sagepub.com/doi/10.1191/0961203302lu243oa
- Danza A, Borgia I, Narváez JI, et al. Intravenous pulses of methylprednisolone to treat flares of immune-mediated diseases: how much, how long? Lupus. 2018;27:1177–1184. Available from: http://journals.sagepub.com/doi/10.1177/0961203318768888
- Schmid D, Burmester G-R, Tripmacher R, et al. Bioenergetics of human peripheral blood mononuclear cell metabolism in quiescent, activated, and glucocorticoid-treated states. Biosci Rep. 2000;20(4):289–302.
- Pons-Estel BA, Bonfa E, Soriano ER, et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PA. Ann Rheum Dis. 2018;77:1549–1557. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2018-213512
- Skorpen CG, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2015-208840
- Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76:476–485. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2016-209770
- Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79:713–723. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2020-216924
- Zeher M, Doria A, Lan J, et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus. 2011;20:1484–1493. Available from: http://journals.sagepub.com/doi/10.1177/0961203311418269
- Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72:1280–1286. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2012-202844
- Rovin BH, Solomons N, Pendergraft WF, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019;95:219–231. doi: 10.1016/j.kint.2018.08.025
- Ruiz‐Arruza I, Lozano J, Cabezas‐Rodriguez I, et al. Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long‐term disease control: an observational study. Arthritis Care Res (Hoboken). 2018;70:582–591. Available from: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.23322
- Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C, et al. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev. 2017;16:826–832.
- Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology. 2012;51:1145–1153. Available from: https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/ker410
- Danza A, Graña D, Soto E, et al. Prednisone and long-term damage in systemic lupus erythematosus: which is the threshold dose? A pilot study. Lupus. 2022;31:880–884. Available from: http://journals.sagepub.com/doi/10.1177/09612033221093485
- Ruiz-Irastorza G, Dueña-Bartolome L, Dunder S, et al. Eurolupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritis. Autoimmun Rev. 2021;20:102898. doi: 10.1016/j.autrev.2021.102898
- Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64:797–808. Available from: https://onlinelibrary.wiley.com/doi/10.1002/acr.21664
- Gordon C, Amissah-Arthur M-B, Gayed M, et al. The BSR and BHPR guideline for the management of systemic lupus erythematosus in adults. Rheumatol. 2018;57:e1–e45.
- Strehl C, Buttgereit F. Unraveling the functions of the membrane-bound glucocorticoid receptors: first clues on origin and functional activity. Ann N Y Acad Sci. 2014;1318:1–6.
- Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):753–779.
- Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum. 2003;32:370–377. Available from https://linkinghub.elsevier.com/retrieve/pii/S004901720270111X
- Ruiz-Irastorza G, Danza A, Perales I, et al. Prednisone in lupus nephritis: how much is enough? Autoimmun Rev. 2014;13:206–214. doi: 10.1016/j.autrev.2013.10.013
- Lightstone L, Doria A, Wilson H, et al. Can we manage lupus nephritis without chronic corticosteroids administration? Autoimmun Rev. 2018;17:4–10. doi: 10.1016/j.autrev.2017.11.002
- Ji L, Xie W, Zhang Z. Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual. Rheumatology (Oxford). 2021;60(12):5517–5526.
- Ji L, Xie W, Fasano S, et al. Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis. Lupus Sci Med. 2022;9:e000603. Available from: https://lupus.bmj.com/lookup/doi/10.1136/lupus-2021-000603
- Fasano S, Coscia MA, Pierro L, et al. Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study. Lupus. 2021;30:991–997. Available from: http://journals.sagepub.com/doi/10.1177/09612033211002269
- Ji L, Gao D, Hao Y, et al. Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal. Rheumatology (Oxford). 2023;62:181–189. doi: 10.1093/rheumatology/keac225
- Moroni G, Gallelli B, Quaglini S, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant. 2006;21:1541–1548. doi: 10.1093/ndt/gfk073
- Tselios K, Gladman DD, Su J, et al. Gradual glucocorticosteroid withdrawal is safe in clinically quiescent systemic lupus erythematosus. ACR Open Rheumatol. 2021;3:550–557. Available from: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr2.11267
- Mathian A, Pha M, Haroche J, et al. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. Ann Rheum Dis. 2020;79:339–346. doi: 10.1136/annrheumdis-2019-216303
- Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009;11:R109. Available from: http://arthritis-research.biomedcentral.com/articles/10.1186/ar2764
- Ruiz-Irastorza G, Ugarte A, V EM, et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis. 2007;66:815–817. Available from: https://ard.bmj.com/lookup/doi/10.1136/ard.2006.067777
- Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology. 2020;59:v69–v81. Available from: https://academic.oup.com/rheumatology/article/59/Supplement_5/v69/6024729
- Floris A, Chessa E, Sebastiani GD, et al. Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study. RMD Open. 2022;8:e002701. Available from: https://doi.org/10.1136/rmdopen-2022-002701
- Ruiz-Irastorza G. Prednisone in systemic lupus erythematosus: taper quickly, withdraw slowly. Rheumatology (Oxford). 2021;60(12):5489–5490.